Thanks to LIPIDACTIVE TECHNOLOGY, a biomimetic complex of 15 essential lipids identified as deficient in atopic skin through lipidomics research (Cavallo et al., 2024), it immediately replenishes the lipid deficiency, restores hydration and reduces the itching sensation caused by dryness. TSLP-TARGET helps biologically reduce TSLP (14), a key mediator involved in nerve activation and type 2 inflammation responsible for itching and discomfort.

At the same time, the patented SKIN BARRIER SEALER technology helps strengthen tight junctions (10), improving skin cohesion to help provide lasting relief from itching associated with dry skin and limit the penetration of irritants and allergens. The SHIELD-EFFECT FORMULA, featuring patented SKIN BARRIER THERAPY™ technology, forms a protective shield against environmental factors (allergens and irritants) (2,3) and Staphylococcus aureus, reducing its proliferation as a biofilm (4). Thanks to its 100% biomimetic and biologically active oil phase, made using LIPIDACTIVE technology, which stimulates the natural synthesis of ceramides (9), loricrin and filaggrin (8), the formula progressively helps rebuild the skin barrier, reduces transepidermal water loss, and continuously improves skin comfort, appearance and quality of life.

• New addition to the Bioderma Atoderm AD range
• Designed for very dry skin prone to atopy and eczema
• Rich balm texture
• Atoderm AD Intensive Baume provides dual immediate and long-term action, targeting both the biological causes and external factors that trigger atopic dermatitis.